Difference between revisions of "Malignant solid neoplasm, RET-mutated"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "ESMO-MCBS (3)</span>]''' |- |}" to "ESMO-MCBS (3)</span>]''' |- |} -->") |
Warner-admin (talk | contribs) m (Text replacement - "{| class="wikitable" style="margin:auto; color:white; background-color:#1B4F26"" to "<!-- {| class="wikitable" style="margin:auto; color:white; background-color:#1B4F26"") |
||
| Line 19: | Line 19: | ||
|- | |- | ||
|[https://doi.org/10.1016/s1470-2045(22)00541-1 Subbiah et al. 2022 (LIBRETTO-001)] | |[https://doi.org/10.1016/s1470-2045(22)00541-1 Subbiah et al. 2022 (LIBRETTO-001)] | ||
| − | {| class="wikitable" style="margin:auto; color:white; background-color:#1B4F26" | + | <!-- {| class="wikitable" style="margin:auto; color:white; background-color:#1B4F26" |
|'''[https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards/scorecard-357-1 <span style="color:white;">ESMO-MCBS (3)</span>]''' | |'''[https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards/scorecard-357-1 <span style="color:white;">ESMO-MCBS (3)</span>]''' | ||
|- | |- | ||
Revision as of 15:22, 6 October 2023
1 regimens on this page
1 variants on this page
|
Advanced or metastatic disease, all lines of therapy
Selpercatinib monotherapy
Regimen
| Study | Dates of enrollment | Evidence |
|---|---|---|
| Subbiah et al. 2022 (LIBRETTO-001) | 2017-12-04 to 2021-08-04 | Phase 1/2 (RT) |
Note: this is the phase 2 recommended dosing.
References
- LIBRETTO-001: Subbiah V, Wolf J, Konda B, Kang H, Spira A, Weiss J, Takeda M, Ohe Y, Khan S, Ohashi K, Soldatenkova V, Szymczak S, Sullivan L, Wright J, Drilon A. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. Lancet Oncol. 2022 Oct;23(10):1261-1273. Epub 2022 Sep 12. link to original article PubMed NCT03157128